AGIO stock icon

Agios Pharmaceuticals
AGIO

$45.88
3.36%
 

About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Employees: 386

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

63% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 24

35% more capital invested

Capital invested by funds: $1.29B [Q4 2023] → $1.74B (+$451M) [Q1 2024]

9% more funds holding

Funds holding: 167 [Q4 2023] → 182 (+15) [Q1 2024]

2.41% more ownership

Funds ownership: 103.38% [Q4 2023] → 105.79% (+2.41%) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 56

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 2 (+0) [Q1 2024]

20% less call options, than puts

Call options by funds: $12.5M | Put options by funds: $15.5M

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$30
35%
downside
Avg. target
$43
7%
downside
High target
$53
16%
upside

6 analyst ratings

positive
33%
neutral
67%
negative
0%
JP Morgan
Tessa Romero
0%upside
$46
Neutral
Reinstated
13 Jun 2024
Goldman Sachs
Salveen Richter
16%upside
$53
Neutral
Maintained
4 Jun 2024
RBC Capital
Gregory Renza
16%upside
$53
Outperform
Maintained
4 Jun 2024
Goldman Sachs
Salveen Richter
28%downside
$33
Neutral
Maintained
3 May 2024
JP Morgan
Tessa Romero
35%downside
$30
Neutral
Maintained
23 Feb 2024

Financial journalist opinion